Contains Nonbinding Recommendations

Draft Guidance on Maraviroc

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient:  Maraviroc

Dosage Form; Route:  Tablet; oral

Recommended Studies:  Two studies

1. Type of study:  Fasting  
   Design:  Single-dose, two-treatment, two-period crossover in vivo  
   Strength:  300 mg  
   Subjects:  Males and non-pregnant, non-lactating females, general population  
   Additional comments: None

2. Type of study:  Fed  
   Design:  Single-dose, two-treatment, two-period crossover in vivo  
   Strength:  300 mg  
   Subjects:  Males and non-pregnant, non-lactating females, general population  
   Additional comments: None

Analyte to measure:  Maraviroc in plasma

Bioequivalence based on (90% CI):  Maraviroc

Waiver request of in vivo testing:  25 mg, 75 mg, and 150 mg strengths based on (i) acceptable bioequivalence studies on the 300 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths

Dissolution test method and sampling times:  The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location:  http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units for each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.